Pharsight

1. Vazalore patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8865187	January, 2014	Decision	Lenard M. Lichtenberger

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101637	PLX PHARMA	Methods of treating inflammation with compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity	Mar, 2022 (1 year, 6 months ago)
US8865187	PLX PHARMA	Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity	Mar, 2022 (1 year, 6 months ago)
US10786444	PLX PHARMA	PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same	Sep, 2032 (9 years from now)
US10646431	PLX PHARMA	PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same	Sep, 2032 (9 years from now)
US9226892	PLX PHARMA	pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same	Sep, 2032 (9 years from now)
US9216150	PLX PHARMA	pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same	Sep, 2032 (9 years from now)

Drugs and Companies using ASPIRIN ingredient

Market Authorisation Date: 14 January, 2013

Treatment: Treatment/prevention of cardiovascular disease; Temporary reduction of fever; Temporary relief of minor aches and pains; A method of targeting release of a non-steroidal anti-inflammatory drug (nsaid)...

Dosage: CAPSULE;ORAL